Share This Author
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
- Y. Wu, C. Zhou, Y. Zuo
- Medicine, BiologyAnnals of oncology : official journal of the…
- 1 September 2015
It is demonstrated that first-line erlotinib provides a statistically significant improvement in PFS versus GP in Asian patients with EGFR mutation-positive NSCLC (NCT01342965).
Radiation-induced injury to the visual pathway.
Maxillary sinus carcinomas: natural history and results of postoperative radiotherapy.
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent…
- Caicun Zhou, Yi-Long Wu, A. Yin
- Medicine, ChemistryJournal of clinical oncology : official journal…
- 26 May 2015
The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC.
Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance.
A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus.
Extent and kinetics of recovery of occult spinal cord injury.
The tolerance of primate spinal cord to re-irradiation.
The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients.
Cell-free DNA detection may be useful in evaluating the effect of preoperative chemoradiotherapy in patients with rectal cancer and was associated with a better tumor response.